c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia

Haematologica. 2015 May;100(5):e179-82. doi: 10.3324/haematol.2014.115691. Epub 2015 Feb 6.

Authors

Claire M Lucas¹, Robert J Harris¹, Athina Giannoudis¹, Richard E Clark²

Affiliations

¹ Department of Haematology, Royal Liverpool and Broadgreen University Hospital, Liverpool, UK.
² Department of Haematology, Royal Liverpool and Broadgreen University Hospital, Liverpool, UK [email protected].

No abstract available

Keywords: 10058-F4; CIP2A; CML; MYC; PP2A.

Publication types

Letter

MeSH terms

Autoantigens / metabolism*
Cell Line, Tumor
Enzyme Activation / drug effects
Fusion Proteins, bcr-abl / metabolism*
Humans
Intracellular Signaling Peptides and Proteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
Membrane Proteins / metabolism*
Proto-Oncogene Proteins c-myc / antagonists & inhibitors*
Proto-Oncogene Proteins c-myc / genetics
RNA Interference
RNA, Small Interfering / genetics
Thiazoles / pharmacology
Thiazoles / therapeutic use

Substances

5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one
Autoantigens
CIP2A protein, human
Intracellular Signaling Peptides and Proteins
Membrane Proteins
Proto-Oncogene Proteins c-myc
RNA, Small Interfering
Thiazoles
Fusion Proteins, bcr-abl